1. Home
  2. JELD vs IMUX Comparison

JELD vs IMUX Comparison

Compare JELD & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JELD-WEN Holding Inc.

JELD

JELD-WEN Holding Inc.

N/A

Current Price

$1.77

Market Cap

152.7M

ML Signal

N/A

Logo Immunic Inc.

IMUX

Immunic Inc.

N/A

Current Price

$7.64

Market Cap

155.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JELD
IMUX
Founded
1960
2016
Country
United States
United States
Employees
N/A
66
Industry
Forest Products
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.7M
155.8M
IPO Year
2016
2013

Fundamental Metrics

Financial Performance
Metric
JELD
IMUX
Price
$1.77
$7.64
Analyst Decision
Hold
Strong Buy
Analyst Count
3
12
Target Price
$1.93
★ $43.09
AVG Volume (30 Days)
★ 1.4M
382.4K
Earning Date
11-02-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 38.00
EPS
★ N/A
N/A
Revenue
★ $3,211,181,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.28
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.93
$0.51
52 Week High
$4.92
$17.43

Technical Indicators

Market Signals
Indicator
JELD
IMUX
Relative Strength Index (RSI) 42.97 21.73
Support Level $1.63 $0.78
Resistance Level $2.18 $15.82
Average True Range (ATR) 0.16 0.65
MACD -0.02 -0.11
Stochastic Oscillator 5.17 0.00

Price Performance

Historical Comparison
JELD
IMUX

About JELD JELD-WEN Holding Inc.

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: